文献速递淋巴瘤

LYMA试验中接受利妥昔单抗维持治疗的年轻套细胞淋巴瘤患者的长期随访:一项LYSA研究

Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
PubMed 文献 · J Clin Oncol · 2023-12-18

LYMA试验长期随访7.5年(95%CI 7.4-7.7)显示,利妥昔单抗维持治疗(RM)较观察显著延长无事件生存(7年76.2% vs 46%,HR 0.39)和无进展生存(7年78.5% vs 47.4%,HR 0.36),总生存7年83.2% vs 72.2%(P=0.088,HR 0.63)。RM未增加感染相关死亡,支持其作为安全的标准治疗。

要点

  • RM组7年EFS 76.2% vs 观察组46%(HR 0.39,P<0.0001)。
  • RM组7年PFS 78.5% vs 观察组47.4%(HR 0.36,P<0.0001)。
  • 7年OS 83.2% vs 72.2%(P=0.088,HR 0.63),RM未增加感染相关死亡。

核心结论

  • 在自体干细胞移植后,利妥昔单抗维持治疗的无进展生存获益在7年随访后仍然存在,且未增加感染相关死亡率,使该策略成为安全的标准治疗。

研究设计与样本

  • LYMA试验的长期随访更新,纳入初治年轻套细胞淋巴瘤患者,比较利妥昔单抗维持治疗与观察。
  • 自入组起中位随访7.5年(95%CI 7.4-7.7)。

主要发现

  • 全人群中位无进展生存和总生存均未达到,7年PFS为55.5%(95%CI 49.5-61),7年OS为69.5%(95%CI 63.8-74.5)。
  • EFS:RM组中位未达到 vs 观察组5.8年(P<0.0001;HR 0.39,95%CI 0.52-0.6),7年估计值RM组76.2% vs 观察组46%。
  • PFS:RM组7年估计值78.5% vs 观察组47.4%(HR 0.36,95%CI 0.23-0.56,P<0.0001)。
  • OS:RM组7年估计值83.2% vs 观察组72.2%(P=0.088,HR 0.63,95%CI 0.37-1.08)。
  • 两组死因无显著差异,淋巴瘤为主要死因,感染相关死亡率极低。

临床怎么用

  • 作者认为,利妥昔单抗维持治疗在长期随访中显示为安全的标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The LYMA trial demonstrated the benefit of rituximab maintenance (RM) in first-line young patients with mantle-cell lymphoma. In this prolonged follow-up of 7.5 years (95% CI, 7.4 to 7.7) from inclusion, the median progression-free survival (PFS) and overall survival (OS) for the full population were not reached (NR) with a 7-year PFS of 55.5% (95% CI, 49.5 to 61) and OS of 69.5% (95% CI, 63.8 to 74.5). The EFS remained statistically superior in favor of RM (median NR v 5.8 years, P < .0001; HR, 0.39 [95% CI, 0.52 to 0.6] and 7-year estimate, 76.2% versus 46% for RM and observation, respectively). Similarly, RM prolonged PFS (estimated PFS at 7 years, 78.5% v 47.4% and HR, 0.36 [95% CI, 0.23 to 0.56] for RM and observation, respectively, P < .0001). The 7-year OS estimate was 83.2% versus 72.2%, respectively (P = .088, HR, 0.63 [95% CI, 0.37 to 1.08]). Cause of death was not significantly distinct between the two groups, with lymphoma being the leading cause with a very low rate of infection-related death. Overall, the PFS benefit of RM after autologous stem cell transplantation remains after 7-year follow-up, and RM was not associated with an increase in infection-related mortality, making this strategy a safe standard of care with long-term follow-up.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sarkozy C, Thieblemont C, Oberic L, et al. Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study. J Clin Oncol. 2023. PMID: 38109684. doi:10.1200/JCO.23.01586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。